Disease progression patterns of bevacizumab responders with recurrent malignant gliomas

Tumor progression in patients with recurrent malignant glioma who respond to bevacizumab (BEV) is difficult to assess. The current study reviewed the clinical and radiological results of patients following a BEV-based chemotherapy regimen, and evaluated disease progression patterns in patients who r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ju-Hwi, Jung, Tae-Young, Hwang, Eu Chang, Jung, Sung-Hoon, Jung, Shin, Kim, In-Young, Jang, Woo-Youl, Moon, Kyung-Sub, Lee, Kyung-Hwa, Kim, Seul-Kee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588053/
https://www.ncbi.nlm.nih.gov/pubmed/28927109
http://dx.doi.org/10.3892/ol.2017.6630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588053/
https://www.ncbi.nlm.nih.gov/pubmed/28927109
http://dx.doi.org/10.3892/ol.2017.6630

Ejemplares similares